Medicus Pharma Announces Plans for CD228V Co-development and Skinject IPO
MDCX Medicus Pharma Ltd
$1.88 +0.80%
View chart & analysis → - 1Medicus Pharma has signed a co-development and licensing agreement for CD228V with Pfizer.
- 2The company proposed a transaction for Skinject, valued at approximately $135 million, with an undisclosed SPAC.
- 3Medicus Pharma raised approximately $42.6 million through equity and secured debt financing for the nine-month period ended September 30, 2026.
So what's the key point?
Medicus Pharma decided to develop a new drug together with Pfizer. The company also planned to take Skinject public and raise about $42.6 million.
Source ACCESSWIRE +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.